HCAR2 anticorps (Middle Region)

N° du produit ABIN952597

Détail du produit anti-HCAR2 anticorps

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Épitope: AA 207-236, Middle Region

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HCAR2 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificité: This antibody recognizes Human GRP109A (Center). Other species not tested.

Purification: Protein A column, followed by peptide affinity purification

Immunogène: KLH conjugated synthetic peptide between 207-236 amino acids from the Central region of human GPR109A Genename: NIACR1

Isotype: Ig Fraction

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur HCAR2

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Autre désignation: GPR109A (HCAR2 Produits)

Synonymes: anticorps GPR109A, anticorps HCA2, anticorps HM74a, anticorps HM74b, anticorps NIACR1, anticorps PUMAG, anticorps Puma-g, anticorps Gpr109a, anticorps Gpr109b, anticorps HM74, anticorps Hcar2, anticorps PUMA-G, anticorps Pumag, anticorps mHM74b, anticorps HCAR2, anticorps HCAR3, anticorps hydroxycarboxylic acid receptor 2, anticorps HCAR2, anticorps Hcar2, anticorps LOC527744

Sujet: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamideSynonyms: G-protein coupled receptor 109A, G-protein coupled receptor HM74A, HM74A, NIACR1, Niacin receptor 1, Nicotinic acid receptor, PUMA-G, Pumag

Poids moléculaire: 41850 Da

ID gène: 338442

NCBI Accession: NP_808219